# SAM #36C25027Q0052

VA market research for unit-dose radiopharmaceuticals in Cleveland and Kent

**Buyer:** VA Network Contracting Office 10
**Posted:** October 19, 2026
**Respond By:** November 03, 2026
**Identifier:** 36C25027Q0052
**NAICS:** 325412, 424210

The Department of Veterans Affairs is conducting market research for unit-dose radiopharmaceutical supply to its Cleveland and Kent, Ohio, healthcare locations.
- **Government buyer:** Department of Veterans Affairs; VA Northeast Ohio Healthcare System and VA Kent Imaging and Infusion Center; Network Contracting Office 10.
- **OEMs and vendors:** No manufacturers or vendors are named. Respondents are expected to identify the manufacturers they would supply and provide manufacturer authorization letters.
- **Requested products:** 29 types of patient-specific, low-energy radiopharmaceuticals and related kits or vials, excluding FDG F-18 agents. Annual estimated quantities are listed below; the largest is 5,000 doses of 99mTc Sestamibi.
- **Notable requirements:** Products must be prepared and calibrated by or under a certified Nuclear Pharmacist, meet applicable USP and regulatory requirements, and be properly labeled with a barcode. Suppliers must hold applicable radioactive-material, FDA, DOT, and other required authorizations, support routine orders, and deliver emergency orders to both locations within 120 minutes.
- **Opportunity context:** This is market research, not a solicitation. The anticipated performance structure is a one-year base period with four one-year options; listed quantities are annual estimates and may vary with demand.

### Description

<div>
  <p><strong>SOURCES SOUGHT NOTICE (36C25027Q0052)</strong><br>
  Low Energy Radiopharmaceuticals (Non-FDG F-18 Agents), Unit Doses<br>
  VA Northeast Ohio Healthcare System (Cleveland, OH) and VA Kent Imaging and Infusion Center (Kent, OH)</p>
</div>

<div>
  <p><strong>Notice Information</strong></p>
  <ul>
    <li><strong>Notice Type:</strong> Sources Sought (Market Research Only)</li>
    <li><strong>Contracting Office:</strong> Department of Veterans Affairs</li>
    <li><strong>NAICS Code:</strong> 325412 — Pharmaceutical Preparation Manufacturing</li>
    <li><strong>Small Business Size Standard:</strong> 1,300 employees</li>
    <li><strong>Product Service Code (PSC):</strong> 6505 — Drugs and Biologicals</li>
    <li><strong>Place of Performance:</strong> Hot Lab Room B-C432, 10701 East Blvd., Cleveland, OH 44106; and Hot Lab Room B109, 3838 Cascades Blvd., Kent, OH 44240</li>
    <li><strong>Anticipated Period of Performance:</strong> Base: 01/01/2027–12/31/2027, plus four (4) 12-month option years (through 12/31/2031)</li>
    <li><strong>Response Due Date/Time:</strong> 9:00 AM Eastern Time, Tuesday, November 3, 2026</li>
    <li><strong>Submit to:</strong> Robert.Blasko@va.gov</li>
  </ul>
</div>

<div>
  <p><strong>1. PURPOSE / DISCLAIMER</strong></p>
  <p>This is a Sources Sought Notice (SSN) issued for market research purposes only in accordance with FAR Part 10. It is <strong>NOT</strong> a solicitation, a request for proposal, a request for quotation, or an invitation for bid, and it does not commit the Government to issue a solicitation or award any contract. The Government will not pay for any information submitted in response to this notice, and responses will not be returned. Submitting a response does not guarantee participation in any future solicitation.</p>
  <p>The purpose of this notice is to identify qualified sources—including the extent of participation by Service-Disabled Veteran-Owned Small Businesses (SDVOSBs), Veteran-Owned Small Businesses (VOSBs), and other small business concerns—capable of meeting the requirement described below. Responses will assist the Government in determining the appropriate acquisition strategy (including any Veterans First / Rule of Two set-aside determination under VAAR 819.70) and will be used to support acquisition planning under FAR Part 10 and VAAR Part 810.</p>
  <p>This requirement is being conducted under the VA's health-care-resources sharing authority at 38 U.S.C. 8153 and Public Law 104-262.</p>
</div>

<div>
  <p><strong>2. BACKGROUND AND SCOPE</strong></p>
  <p>The VA Northeast Ohio Healthcare System and the VA Kent Imaging and Infusion Center require unit-dose, patient-specific low energy radiopharmaceutical products (non-fluorodeoxyglucose F-18 agents) to support routine (non-emergent) and emergent diagnostic nuclear medicine imaging and limited therapeutic procedures.</p>
  <p>All doses must be compounded and calibrated by or under the supervision of a certified Nuclear Pharmacist and prepared within the required guidelines of the Board of Pharmacy, specifically USP &lt;797&gt; and USP &lt;825&gt; as appropriate. The contractor must follow generally accepted industry standards and the regulations of the applicable governing bodies, which may include the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Food and Drug Administration (FDA), the Nuclear Regulatory Commission (NRC), the Centers for Disease Control and Prevention (CDC), the United States Pharmacopeia (USP), and The Joint Commission (JC).</p>
  <p><strong>Delivery requirement:</strong> The contractor must support both routine and emergent orders (Emergencies). Emergencies may be requested during and outside of regular work hours (Monday through Friday, 06:30 a.m.–4:30 p.m.) and require delivery within 120 minutes after receipt of a phoned, faxed, or electronic order from the VA. The VA also requires prompt processing of Tc-99m tagged white blood cell (WBC) orders. Quantities are estimates and may vary based on patient demand.</p>
</div>

<div>
  <p><strong>3. REQUIRED LICENSURE STATEMENT</strong></p>
  <p>Interested parties must already possess all licenses, registrations, and authorizations required to receive, possess, compound, prepare, transport, distribute, and dispose of the radioactive byproduct material / radiopharmaceutical isotopes described in this notice, and must be regularly established in the business of providing radionuclides. At a minimum, respondents must hold a current, unrevoked Nuclear Regulatory Commission (NRC) and/or applicable Agreement State radioactive materials license authorizing production and distribution of radiopharmaceuticals for human administration, and the authority to receive and dispose of radioactive waste, together with all applicable FDA, U.S. Department of Transportation (DOT), and state and local authorizations.</p>
  <p>Respondents should confirm they currently hold such licensure (and, where applicable, identify the issuing authority and license type) as part of their response. Respondents are not required to submit the full license with this SSN but must affirmatively state that current, valid licensure is in place; copies may be required at the solicitation/award stage.</p>
</div>

<div>
  <p><strong>4. ESTIMATED REQUIREMENT (ANNUAL ESTIMATES)</strong></p>
  <p>The following unit-dose radiopharmaceutical products are required. Quantities are annual estimates based on historical usage for one year and may vary based on patient demand.</p>
  <table>
    <thead>
      <tr><th>Item</th><th>Description</th><th>Est. Annual Qty</th></tr>
    </thead>
    <tbody>
      <tr><td>1</td><td>99mTc Sulfur Colloid</td><td>320</td></tr>
      <tr><td>2</td><td>99mTc MDP</td><td>850</td></tr>
      <tr><td>3</td><td>99mTc Mebrofenin</td><td>110</td></tr>
      <tr><td>4</td><td>99mTc MAG-3</td><td>80</td></tr>
      <tr><td>5</td><td>99mTc Tetrofosmin</td><td>10</td></tr>
      <tr><td>6</td><td>99mTc MAA</td><td>75</td></tr>
      <tr><td>7</td><td>111In Pentreotide</td><td>2</td></tr>
      <tr><td>8</td><td>99mTc04- (Sodium Pertechnetate)</td><td>90</td></tr>
      <tr><td>9</td><td>99mTc Sestamibi</td><td>5,000</td></tr>
      <tr><td>10</td><td>99mTc White Blood Cell Labeling</td><td>90</td></tr>
      <tr><td>11</td><td>111In White Blood Cell Labeling</td><td>2</td></tr>
      <tr><td>12</td><td>99mTc DTPA 30 40 mCi</td><td>60</td></tr>
      <tr><td>13</td><td>99mTc DTPA 0.4 0.7 mCi</td><td>5</td></tr>
      <tr><td>14</td><td>I-123 Iodine Capsules 200 microcuries</td><td>90</td></tr>
      <tr><td>15</td><td>I-123 Iodine Capsules 2 5 millicuries</td><td>12</td></tr>
      <tr><td>16</td><td>UltraTag Kit</td><td>22</td></tr>
      <tr><td>17</td><td>99mTc Filtered Sulfur Colloid: 0.5 1 millicurie</td><td>6</td></tr>
      <tr><td>18</td><td>123I MIBG dose</td><td>2</td></tr>
      <tr><td>19</td><td>Cold PYP vials</td><td>50</td></tr>
      <tr><td>20</td><td>99mTc PYP</td><td>100</td></tr>
      <tr><td>21</td><td>99mTc DMSA</td><td>2</td></tr>
      <tr><td>22</td><td>67Ga Gallium Citrate</td><td>2</td></tr>
      <tr><td>23</td><td>111In DTPA</td><td>2</td></tr>
      <tr><td>24</td><td>99mTc HMPAO</td><td>2</td></tr>
      <tr><td>25</td><td>131I Diagnostic capsule</td><td>10</td></tr>
      <tr><td>26</td><td>131I Therapeutic capsule 1 3 mCi</td><td>12</td></tr>
      <tr><td>27</td><td>131I Therapeutic capsule, each additional mCi</td><td>1,500</td></tr>
      <tr><td>28</td><td>99mTc HDP</td><td>55</td></tr>
      <tr><td>29</td><td>99mTc WBC Blood Kit (Heparin)</td><td>90</td></tr>
    </tbody>
  </table>
  <p>Products must be labeled with the radiopharmaceutical identity, amount/activity, concentration, preparation time, calibration time, total volume, expiration date and time, and must include a bar-code label to facilitate scanning into a Nuclear Medicine Information System (NMIS). Each syringe, vial, syringe shield, and vial shield must be correctly labeled.</p>
</div>

<div>
  <p><strong>5. INFORMATION REQUESTED FROM RESPONDENTS</strong></p>
  <p>Interested and capable firms are invited to submit a response demonstrating their ability to meet this requirement. Responses must include <strong>ALL</strong> of the following:</p>
  <ul>
    <li><strong>Manufacturer Authorized Distribution Letter(s):</strong> Documentation establishing the respondent's authorization to distribute the applicable radiopharmaceutical product(s) (e.g., authorized distributor/dealer letter(s) from the manufacturer(s)).</li>
    <li><strong>Manufacturer's Name(s):</strong> Identify the manufacturer(s) of the radiopharmaceutical product(s) the respondent would supply.</li>
    <li><strong>Business Size and Socioeconomic Status:</strong> State whether the firm is a large or small business under NAICS 325412 (1,300-employee size standard), and identify all applicable socioeconomic categories (e.g., SDVOSB, VOSB, 8(a), HUBZone, WOSB, SDB, or other). SDVOSBs/VOSBs must be certified in the SBA Veteran Small Business Certification program (via the SBA Search for Certified Businesses (SBS)).</li>
    <li><strong>Ability to Provide ALL Items:</strong> State clearly whether the firm can provide ALL of the items listed in Section 4. If the firm can provide only a portion, identify specifically which item(s) it can and cannot supply.</li>
    <li><strong>GSA / NAC / SAC Availability:</strong> State whether the item(s) are available on a GSA Schedule, a VA National Acquisition Center (NAC) contract, or a VA Strategic Acquisition Center (SAC) / MSPV contract vehicle, and provide the applicable contract number(s) if so.</li>
    <li><strong>SAM Unique Entity Identifier (UEI):</strong> Provide the firm's SAM.gov UEI. Respondents must be actively registered in SAM.gov (www.sam.gov).</li>
    <li><strong>Current Licensure Confirmation:</strong> An affirmative statement that the firm currently holds all required NRC and/or Agreement State, FDA, and DOT licenses/authorizations to receive, compound, prepare, transport, distribute, and dispose of the radiopharmaceutical isotopes described herein (see Section 3), including the issuing authority and license type where applicable.</li>
    <li><strong>Positive Acknowledgement of Delivery Capability:</strong> A positive, affirmative statement that the firm can deliver in accordance with ALL SOW requirements, including the ability to fulfill emergent orders within 120 minutes of receipt to both the Cleveland and Kent locations, and to provide unit doses compounded/calibrated by or under a certified Nuclear Pharmacist in accordance with USP &lt;797&gt;/&lt;825&gt; and all applicable NRC/FDA/DOT/state regulations. Respondents are encouraged to identify the location(s) of the radiopharmacy(ies) from which they would service both sites.</li>
  </ul>
  <p><strong>Additional information requested (optional but helpful):</strong> Company name, address, point of contact (name, title, phone, email); a brief capability statement; and any relevant prior experience providing unit-dose radiopharmaceuticals to federal or commercial healthcare customers.</p>
</div>

<div>
  <p><strong>6. SUBMISSION INSTRUCTIONS</strong></p>
  <ul>
    <li><strong>Response due date/time:</strong> 9:00 AM Eastern Time, Tuesday, November 3, 2026. Responses received after this date and time may not be considered.</li>
    <li><strong>Format:</strong> Submit responses electronically to the Contracting Officer / Contract Specialist identified in the SAM.gov posting (Robert.Blasko@va.gov). Reference this Sources Sought Notice number (36C25027Q0052) in the subject line.</li>
    <li><strong>Page/content:</strong> Address each item in Section 5, in order. Capability statements should be concise.</li>
    <li><strong>Questions:</strong> Direct any questions to the point of contact listed in the SAM.gov posting (Robert.Blasko@va.gov) prior to the response due date.</li>
  </ul>
</div>

<div>
  <p><strong>7. IMPORTANT NOTES</strong></p>
  <p>This notice does not restrict the Government to any particular acquisition approach. Based on the responses received, the Government will determine whether the requirement can be set aside for SDVOSBs, VOSBs, or other small business concerns consistent with the Veterans First Contracting Program (VAAR 819.70) and the Rule of Two, or whether another acquisition strategy is appropriate.</p>
  <p>Respondents are advised that the Nonmanufacturer Rule (13 CFR 121.406) and Limitations on Subcontracting (FAR 52.219-14 / 52.219-33) apply to any resulting SDVOSB/VOSB set-aside or sole-source award above the micro-purchase threshold. Respondents should be prepared to address their status (manufacturer vs. nonmanufacturer) under these rules.</p>
  <p>All prospective offerors must be registered in SAM.gov to be eligible for any resulting award.</p>
  <p>The applicable Buy American Act / Trade Agreements Act provisions will apply to any resulting solicitation; respondents may be required to provide a Buy American Act certificate and country-of-origin information at the solicitation stage.</p>
  <p><strong>THIS IS A SOURCES SOUGHT NOTICE / MARKET RESEARCH ONLY — NOT A SOLICITATION.</strong></p>
</div>

[View original listing](https://sam.gov/opp/15fafc99ab5b43e4afc21e7f8067d07b/view)